Registered title, quoted from ClinicalTrials.gov
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
An open trial on Ewing sarcoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 4 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 4
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
- Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
- Study siteZhejiang Provincial People's Hospital浙江省人民医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06926283, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Have received systemic antineoplastic therapy or investigational product treatment within 28 days or 5 half-lives (whichever is shorter) prior to the first dose, have received radiotherapy within 14 days prior to the first dose.
Exclusion criterion 2
Have received monoclonal antibody therapy for anti-tumor purposes within 30 days prior to the first dose.
Exclusion criterion 3
Those with active infection requiring drug intervention (CTCAE ≥ Grade 2) within 2 weeks prior to the first dose of study treatment, uncontrollable pleural effusion, ascites, pericardial effusion requiring repeated drainage.
Exclusion criterion 22
ECOG performance status score: 0-2.
Inclusion criterion 5
ANC ≥ 1.5 × 10\^9/L (prior use of G-CSF is allowed, but G-CSF use is not allowed within 7 days prior to the screening laboratory tests).
Inclusion criterion 11
Platelet count ≥100×10\^9/L (platelet transfusion is not allowed within 7 days before the screening laboratory tests).
Inclusion criterion 12
Total bilirubin (TBIL) ≤1.5×ULN, except for subjects with congenital bilirubinemia, such as Gilbert syndrome (direct bilirubin ≤1.5×ULN).
Inclusion criterion 14
AST and ALT ≤ 3.0 × ULN.For patients with liver metastases, both AST and ALT ≤5×ULN.
Inclusion criterion 15
APTT or PT ≤ 1.5 × ULN. LVEF≥50%.
Inclusion criterion 17
History of other primary malignancies, except for the following: malignancies that have been cured and have a very low risk of recurrence within 5 years, such as basal cell carcinoma and squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast.
Exclusion criterion 14
Active hepatitis B with HBV-DNA greater than central upper limit of normal or greater than 1000 copies/mL, active hepatitis C (Hepatitis C virus antibody positive with HCV RNA greater than lower limit of detection value).
Exclusion criterion 17
Known to be seropositive for the HIV; have active syphilis (only patients with a positive syphilis antibody are eligible for enrollment in the study), possible presence of active tuberculosis (chest imaging within 3 months prior to the first dose indicates active tuberculosis infection).
Exclusion criterion 18
Subjects and their spouses agree to use effective instrumental or pharmacologic contraception (excluding safe period contraception) from the time of ICF signing until 6 months after the last dose of investigational product.
Inclusion criterion 18
Female subjects with positive serum pregnancy test or who are breastfeeding.
Exclusion criterion 21
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06926283, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Those who voluntarily sign the ICF and follow the protocol requirements.
- Male or female.
- Age: ≥ 18 years and ≤ 75 years.
- Expected life expectancy ≥ 6 months.
- ECOG performance status score: 0-2.
- Patients with various solid tumors who have failed standard treatment, including but not limited to progressive mCRPC.
- Prostate Cancer: Serum testosterone level during screening and prior to the first dose of investigational product: ≤50 ng/dL (≤1.73 nmol/L).
- Prostate Cancer is divided into two cohorts: Cohort 1: At least one measurable lesion as defined by RECIST v1.1. Cohort 2: At least one metastatic lesion on CT/MRI, or bone scan imaging at baseline.Patients are assigned to the appropriate cohort as assessed by the investigator; the study procedures in Cohort 1 and Cohort 2 may be performed in parallel and simultaneously,it is not necessary to wait until all procedures in either cohort have been completed before initiating procedures in the other cohort.Other solid tumors:At least one measurable lesion as defined by RECIST v1.1.
- Toxicities from prior antitumor therapy must have recovered to Grade ≤ 1 as defined in the NCI-CTCAE v5.0 (except alopecia), or Grade 2 as defined by NCI-CTCAE v5.0, except for toxicity not constituting a safety risk by investigator judgment (eg, Grade 2 peripheral neurotoxicity).
- Organ function of the subjects must meet the following requirements:
Hematology:
- ANC ≥ 1.5 × 10\^9/L (prior use of G-CSF is allowed, but G-CSF use is not allowed within 7 days prior to the screening laboratory tests).
- Platelet count ≥100×10\^9/L (platelet transfusion is not allowed within 7 days before the screening laboratory tests).
- HGB ≥ 90 g/L (RBC transfusion or recombinant human erythropoietin use is allowed; RBC transfusion is not allowed within 7 days prior to the screening laboratory tests).
Liver function:
- Total bilirubin (TBIL) ≤1.5×ULN, except for subjects with congenital bilirubinemia, such as Gilbert syndrome (direct bilirubin ≤1.5×ULN).
- AST and ALT ≤ 3.0 × ULN.For patients with liver metastases, both AST and ALT ≤5×ULN.
Renal function:
Ccr ≥ 60 mL/min; or creatinine ≤ 1.5 × ULN; urinalysis results show protein urine ≤ 1 +. For subjects with urine protein ≥2+ in urinalysis during the screening period, a 24-hour urine protein quantification should be performed, and those with 24-hour urine protein quantification ≤1 g can be enrolled.
Coagulation function:
- INR≤1.5.
- APTT or PT ≤ 1.5 × ULN. LVEF≥50%.
- Subjects and their spouses agree to use effective instrumental or pharmacologic contraception (excluding safe period contraception) from the time of ICF signing until 6 months after the last dose of investigational product.
Exclusion Criteria:
- Within 14 days prior to the first dose: Have undergone plasmapheresis, treated with prednisone at > 10 mg/day for > 3 consecutive days or equivalent dose of systemic corticosteroids or equivalent anti-inflammatory medication (Those who have received short-term treatment with such medications for the prevention of contrast media allergy may be enrolled).
- Have received systemic antineoplastic therapy or investigational product treatment within 28 days or 5 half-lives (whichever is shorter) prior to the first dose, have received radiotherapy within 14 days prior to the first dose.
- Have received monoclonal antibody therapy for anti-tumor purposes within 30 days prior to the first dose.
- History of solid organ transplantation.
- Ewing sarcoma:Prior treatment with XXX-targeted therapy (in Phase Ia clinical study only) Other olid tumors:Prior treatment with XXX-targeted therapy or topoisomerase inhibitors (in Phase Ia clinical study only).
- Presence of meningeal or brain metastases.
- Evidence of cardiovascular risk, including any of the following:
- QTcF interval ≥ 470 msec (QT interval must be corrected for heart rate using the Fridericia formula [QTcF]).
- Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including second-degree (Mobitz Type II) or third-degree atrioventricular (AV) block.
- Within 6 months before screening, history of myocardial infarct, acute coronary syndrome (including unstable angina pectoris), coronary angioplasty or stent implantation, or bypass grafting.
- Class III or IV heart failure - as defined by the New York Heart Association Functional Classification.
- Uncontrolled severe hypertension: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg.
- Have dyspnea or any current condition that needs continuous oxygen therapy, or current active pneumonia or interstitial lung diseases (except mild cases as judged by the investigator).
- History of other primary malignancies, except for the following: malignancies that have been cured and have a very low risk of recurrence within 5 years, such as basal cell carcinoma and squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast.
- Have severe unhealed wound, ulceration or bone fracture, or have received major surgery within 28 days prior to administration or expected major surgery during the clinical study.
- Prior history of allergy to any component or excipient of DXC008.
- Active hepatitis B with HBV-DNA greater than central upper limit of normal or greater than 1000 copies/mL, active hepatitis C (Hepatitis C virus antibody positive with HCV RNA greater than lower limit of detection value).
- Known to be seropositive for the HIV; have active syphilis (only patients with a positive syphilis antibody are eligible for enrollment in the study), possible presence of active tuberculosis (chest imaging within 3 months prior to the first dose indicates active tuberculosis infection).
- Patients with active bleeding within 30 days before screening, or, judged by the investigator, to be at risk of massive digestive tract hemorrhage, hemoptysis, etc.; or with hereditary bleeding tendency or coagulation disorder, or bleeding symptoms requiring other medical intervention.
- Have experienced serious arterial/venous thrombosis events within 6 months prior to the first dose, such as cerebrovascular accident (including transient cerebral ischemic attack), deep venous thrombosis, pulmonary embolism.
- Female subjects with positive serum pregnancy test or who are breastfeeding.
- Those with active infection requiring drug intervention (CTCAE ≥ Grade 2) within 2 weeks prior to the first dose of study treatment, uncontrollable pleural effusion, ascites, pericardial effusion requiring repeated drainage.
- Have received vaccination with live attenuated vaccine within 28 days prior to the first dose or planned to receive such vaccination during the study period.
- Patients with other conditions judged by the investigator that may have adverse effect on the patient's participation in the study.
Quoted from ClinicalTrials.gov, NCT06926283, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06926283, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.